HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

NCT07587034 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

315

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

PROCEDURE: HTAC
PROCEDURE: HAC
PROCEDURE: TAC

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]